Table 4 Subgroup analysis for effect of white blood cell on risks of renal function decline, rapid eGFR decline or incident CKD
Variable | Renal Function Decline | Rapid eGFR Decline | Incident CKD | ||||||
|---|---|---|---|---|---|---|---|---|---|
Incidence, n(%) | OR (95% CI) | P-interaction | Incidence, n(%) | OR (95% CI) | P-interaction | Incidence, n(%) | OR (95% CI) | P-interaction | |
Sex | |||||||||
Male | 88 (6.5%) | 1.10 (0.97, 1.26) | 0.5244 | 244 (18.0%) | 1.11 (1.01, 1.21) | 0.9709 | 9 (0.7%) | 1.57 (1.06, 2.32) | 0.4362 |
Female | 204 (8.4%) | 1.16 (1.06, 1.27) | 543 (22.5%) | 1.11 (1.04, 1.18) | 21 (0.9%) | 1.30 (1.02, 1.66) | |||
Age, years | |||||||||
< 60 | 195 (7.4%) | 1.10 (1.00, 1.21) | 0.1517 | 543 (20.5%) | 1.07 (1.00, 1.14) | 0.0398 | 7 (0.3%) | 1.51 (1.00, 2.27) | 0.5985 |
≥ 60 | 97 (8.6%) | 1.23 (1.09, 1.39) | 244 (21.7%) | 1.20 (1.09, 1.32) | 23 (2.0%) | 1.32 (1.03, 1.69) | |||
BMI, kg/m2 | |||||||||
< 28 | 212 (7.6%) | 1.13 (1.03, 1.23) | 0.6299 | 577 (20.6%) | 1.12 (1.06, 1.19) | 0.4084 | 23 (0.8%) | 1.30 (1.02, 1.67) | 0.4080 |
≥ 28 | 80 (8.3%) | 1.18 (1.02, 1.36) | 210 (21.7%) | 1.07 (0.96, 1.18) | 7 (0.7%) | 1.61 (1.04, 2.47) | |||
Baseline eGFR, mL/min/1.73 m2 | |||||||||
Low (<102.5) | 166 (8.8%) | 1.18 (1.07, 1.31) | 0.2632 | 356 (18.9%) | 1.13 (1.05, 1.22) | 0.4544 | 28 (1.5%) | 1.38 (1.11, 1.72) | 0.8913 |
High (≥102.5) | 126 (6.7%) | 1.09 (0.97, 1.22) | 430 (22.8%) | 1.09 (1.01, 1.17) | 2 (0.1%) | 1.31 (0.57, 2.97) | |||
Current smoking | |||||||||
No | 247 (8.1%) | 1.16 (1.07, 1.27) | 0.3243 | 677 (22.1%) | 1.11 (1.05, 1.18) | 0.9003 | 27 (0.9%) | 1.37 (1.10, 1.70) | 0.9942 |
Yes | 45 (6.3%) | 1.06 (0.89, 1.26) | 110 (15.5%) | 1.10 (0.98, 1.24) | 3 (0.4%) | 1.37 (0.76, 2.48) | |||
Current drinking | |||||||||
No | 238 (8.2%) | 1.17 (1.08, 1.28) | 0.1173 | 640 (22.0%) | 1.12 (1.05, 1.19) | 0.4544 | 25 (0.9%) | 1.36 (1.08, 1.72) | 0.9549 |
Yes | 54 (6.2%) | 1.01 (0.84, 1.21) | 147 (16.9%) | 1.06 (0.95, 1.20) | 5 (0.6%) | 1.38 (0.86, 2.22) | |||
Hypertension | |||||||||
No | 112 (5.8%) | 1.12 (0.99, 1.26) | 0.6203 | 346 (17.9%) | 1.07 (0.99, 1.16) | 0.2295 | 4 (0.2%) | 1.16 (0.67, 2.02) | 0.4416 |
Yes | 180 (9.8%) | 1.16 (1.05, 1.28) | 441 (24.1%) | 1.14 (1.06, 1.22) | 26 (1.4%) | 1.44 (1.12, 1.84) | |||
Diabetes mellitus | |||||||||
No | 207 (6.6%) | 1.12 (1.02, 1.23) | 0.5148 | 570 (18.3%) | 1.11 (1.05, 1.18) | 0.7693 | 18 (0.6%) | 1.45 (1.08, 1.94) | 0.5844 |
Yes | 85 (13.0%) | 1.18 (1.04, 1.34) | 217 (33.2%) | 1.09 (0.99, 1.21) | 12 (1.8%) | 1.29 (0.94, 1.76) | |||
Dyslipidemia | |||||||||
No | 68 (7.4%) | 1.19 (1.02, 1.39) | 0.5331 | 186 (20.3%) | 1.10 (0.99, 1.22) | 0.8334 | 5 (0.5%) | 1.62 (0.95, 2.75) | 0.5003 |
Yes | 215 (7.8%) | 1.13 (1.03, 1.23) | 583 (21.1%) | 1.11 (1.05, 1.18) | 25 (0.9%) | 1.32 (1.05, 1.67) | |||
Cardiovascular disease | |||||||||
No | 240 (7.3%) | 1.14 (1.05, 1.24) | 0.9617 | 657 (20.0%) | 1.10 (1.04, 1.17) | 0.6392 | 18 (0.5%) | 1.44 (1.09, 1.89) | 0.5951 |
Yes | 52 (10.9%) | 1.14 (0.96, 1.35) | 130 (27.3%) | 1.14 (1.00, 1.30) | 12 (2.5%) | 1.28 (0.91, 1.79) | |||
Antihypertensive drugs | |||||||||
No | 165 (6.4%) | 1.12 (1.02, 1.24) | 0.5696 | 477 (18.6%) | 1.08 (1.01, 1.16) | 0.2454 | 7 (0.3%) | 1.06 (0.66, 1.70) | 0.2017 |
Yes | 125 (10.6%) | 1.17 (1.04, 1.31) | 305 (25.8%) | 1.15 (1.06, 1.26) | 22 (1.9%) | 1.47 (1.16, 1.86) | |||
Hypoglycemic drugs | |||||||||
No | 239 (7.1%) | 1.14 (1.04, 1.24) | 0.7537 | 648 (19.2%) | 1.11 (1.05, 1.18) | 0.8791 | 20 (0.6%) | 1.52 (1.16, 2.00) | 0.2124 |
Yes | 52 (13.6%) | 1.17 (0.99, 1.38) | 138 (36.1%) | 1.10 (0.97, 1.25) | 10 (2.6%) | 1.12 (0.72, 1.74) | |||
Lipid-lowering drugs | |||||||||
No | 255 (7.6%) | 1.18 (1.09, 1.28) | 0.0541 | 679 (20.4%) | 1.13 (1.07, 1.20) | 0.0872 | 24 (0.7%) | 1.54 (1.20, 1.96) | 0.0677 |
Yes | 34 (8.6%) | 0.94 (0.74, 1.19) | 102 (25.7%) | 0.99 (0.86, 1.15) | 4 (1.0%) | 0.84 (0.40, 1.75) | |||